Mesoblast stock fell 1.68 percent on October 2 2026

Published on 10/04/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mesoblast stock generated USD 120.25 million in fiscal 2026 revenue, up from USD 17.198 million a year earlier. Three analysts rate it Hold.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast (AU000000MSB8) stock last traded at USD 14.08 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 1.68 percent from the prior session. The move leaves the biotechnology company 34.5 percent below its 52-week high of USD 21.50, while its commercial transition is producing a much larger revenue base.

Revenue reaches USD 120.25 million

Mesoblast reported fiscal 2026 revenue of USD 120.25 million for the year ended June 30, 2026, compared with USD 17.198 million in fiscal 2025. The company also reduced its net loss to USD 57.5 million from USD 102.142 million, a 44 percent improvement.

According to Yahoo Finance on August 27, 2026, Ryoncil generated USD 115 million of net revenue in its first full commercial year. Operating cash usage was USD 43.83 million in fiscal 2026, while cash and cash equivalents stood at USD 102.914 million on June 30, 2026.

FDA assay supports Ryoncil supply

On September 24, 2026, the FDA approved a new T-cell Proliferation Inhibition BioAssay for release and stability monitoring of new commercial Ryoncil lots, according to Markets Insider. The assay adds another quality-control measure as Mesoblast develops Ryoncil for additional inflammatory disease indications.

The pipeline remains tied to clinical execution. The fiscal 2026 update cited by Yahoo Finance said 350 patients had completed treatment in a pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain, with results planned for the second half of calendar 2027.

Analyst target stands at USD 39

According to MarketBeat on October 2, 2026, the consensus rating was Hold across three analysts, with two Buy ratings and one Sell rating. The average price target was USD 39.00, which lies 176.99 percent above the USD 14.08 reference price.

Mesoblast stock stays below its yearly high

Mesoblast stock was last at USD 14.08 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 13.05 to USD 21.50, market capitalization was USD 1.8 billion, and trading volume reached 258,345 shares.